CNS Pharmaceuticals (CNSP) Competitors

$0.22
-0.01 (-4.41%)
(As of 05/17/2024 ET)

CNSP vs. CMND, DRMA, ATXI, CYTO, GLMD, SLRX, SNOA, NTBL, ALLR, and ONCO

Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Clearmind Medicine (CMND), Dermata Therapeutics (DRMA), Avenue Therapeutics (ATXI), Altamira Therapeutics (CYTO), Galmed Pharmaceuticals (GLMD), Salarius Pharmaceuticals (SLRX), Sonoma Pharmaceuticals (SNOA), Notable Labs (NTBL), Allarity Therapeutics (ALLR), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.

CNS Pharmaceuticals vs.

Clearmind Medicine (NASDAQ:CMND) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.

In the previous week, CNS Pharmaceuticals had 4 more articles in the media than Clearmind Medicine. MarketBeat recorded 4 mentions for CNS Pharmaceuticals and 0 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.47 beat CNS Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Clearmind Medicine Neutral
CNS Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
CNS Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

CNS Pharmaceuticals received 46 more outperform votes than Clearmind Medicine when rated by MarketBeat users.

CompanyUnderperformOutperform
Clearmind MedicineN/AN/A
CNS PharmaceuticalsOutperform Votes
46
70.77%
Underperform Votes
19
29.23%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$8.62MN/AN/A
CNS PharmaceuticalsN/AN/A-$18.85M-$3.48-0.06

CNS Pharmaceuticals' return on equity of -265.38% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -265.38% -121.95%
CNS Pharmaceuticals N/A -603.40%-575.33%

Clearmind Medicine has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.78, suggesting that its share price is 178% more volatile than the S&P 500.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 9.2% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CNS Pharmaceuticals beats Clearmind Medicine on 5 of the 9 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSP vs. The Competition

MetricCNS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.57M$6.73B$5.30B$7.96B
Dividend YieldN/A2.61%43.94%3.91%
P/E Ratio-0.0622.40154.7018.77
Price / SalesN/A251.762,362.9377.92
Price / CashN/A36.3936.6031.98
Price / Book-0.595.895.754.76
Net Income-$18.85M$130.47M$106.86M$217.17M
7 Day Performance10.94%1.50%1.41%2.90%
1 Month Performance5.85%3.75%4.29%6.57%
1 Year Performance-83.93%-1.19%7.61%10.17%

CNS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
0 of 5 stars
$1.29
flat
N/A-93.2%$2.18MN/A0.00N/APositive News
DRMA
Dermata Therapeutics
0 of 5 stars
$0.34
-10.6%
N/A-89.6%$2.24MN/A-0.098Stock Split
News Coverage
ATXI
Avenue Therapeutics
0.7475 of 5 stars
$3.84
-2.8%
N/A-95.4%$2.27MN/A-0.043Positive News
Gap Down
CYTO
Altamira Therapeutics
0 of 5 stars
$1.44
flat
N/A-91.0%$2.28M$320,000.000.0010Gap Up
GLMD
Galmed Pharmaceuticals
0 of 5 stars
$0.40
+5.2%
N/A-91.3%$2.04MN/A-0.123Analyst Forecast
Short Interest ↑
News Coverage
SLRX
Salarius Pharmaceuticals
1.0193 of 5 stars
$0.46
-6.2%
N/A-65.4%$2.34M$1.84M-0.102Positive News
Gap Up
SNOA
Sonoma Pharmaceuticals
2.2944 of 5 stars
$0.15
flat
$3.25
+2,045.2%
-76.9%$2.36M$12.31M-0.169News Coverage
Positive News
Gap Down
NTBL
Notable Labs
3.1821 of 5 stars
$1.10
-7.6%
$8.00
+627.3%
N/A$2.44M$310,000.00-0.3013Upcoming Earnings
Analyst Forecast
News Coverage
Gap Down
ALLR
Allarity Therapeutics
0.2309 of 5 stars
$0.79
-1.3%
N/A-99.8%$1.89MN/A0.005Gap Down
High Trading Volume
ONCO
Onconetix
0 of 5 stars
$0.11
flat
N/AN/A$2.48M$60,000.00-0.1012News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:CNSP) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners